, to the extent that e-commerce social platform Xiaohongshu installed a pop-up alert telling those searcing for the drug to"go to formal medical facilities for treatment," per CNN.
The platform has also deleted thousands of posts by people sharing their experiences with the drug, CNN reported. China's medical industry is now rushing to catch up, with one company, Huadong Medicine Co, challenging semaglutide manufacturer Novo Nordisk for its patent, Bloomberg reported. Subscribe to push notifications
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: